Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2023 - Eribulin in metastatic breast cancer the UK experience,- a multi-centre retrospective 577 patient study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Mariam Jafri

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

M. Jafri1, H. Kristeleit2, V. Misra3, M.A. Baxter4, S. Ahmed5, A. Jegnnathen6, A. Jain7, D. Maskell8, U. Barthakur9, G. Edwards10, H. Walter11, R. Walter3, M.A. Khan12, A. Borley10, P. Nightingale1, D. Rea13

Author affiliations

  • 1 Medical Oncology, Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, B15 2TH - Birmingham/GB
  • 2 Medical Oncology, Guy's Cancer Centre, London/GB
  • 3 Clinical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 4 Medical Oncology, Beatson West of Scotland Cancer Centre, G12 0YN - Glasgow/GB
  • 5 Leicester Cancer Research Centre, University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, LE1 5WW - Leicester/GB
  • 6 Clinical Oncology, University Hospitals of North Midlands, Stoke/GB
  • 7 Oncology, The Royal Wolverhampton Hospitals NHS Trust New Cross Hospital, WV10 0QP - Wolverhampton/GB
  • 8 Oncology, Norfolk and Norwich University Hospitals, Norfolk - GB/GB
  • 9 Medical Oncology, Taunton and Somerset NHS Foundation Trust, Taunton/GB
  • 10 Clinical Oncology, Velindre Cancer Centre, Cardiff/GB
  • 11 Medical Oncology, University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, LE1 5WW - Leicester/GB
  • 12 Oncology, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 13 Clinical Trials Unit, The University of Birmingham Institute for Cancer Studies, B15 2TT - Birmingham/GB
More

Resources

Abstract 2023

Background

The EMBRACE trial demonstrated significantly improved survival with eribulin compared to physicians’ choice (13.1 vs 10.9 months (p = 0.041). Eribulin has been funded by the NHS in the UK for the management of locally advanced or metastastic breast cancer after at least two lines of treatment. We describe the UK experience of eribulin in this setting.

Methods

Data from 577 patients was analyzed on an individual patient basis from 14 different hospitals after institutional review board approval. Data was collected retrospectively using computerized records and chemotherapy records. Data was collated on: age, breast cancer characteristics, prior chemotherapy regimes, toxicity, PFS and OS. Statistical analysis was performed using SPSS.

Results

Data from 577 patients who received eribulin in specialist cancer centres, teaching hospitals and cancer units throughout the UK between 2011-2017 were included. The median age of patients was 56 (33-84). 447 were ER positive, 129 triple negative, 100 patients were Her2 positive, 1 unknown. The cohort was heavily pre-treated with eribulin being received on average 4thline (median (range 2-11)). The median number of eribulin cycles received were 4 (range 1-29). The OS of the cohort was 288 days (95%CI 260-315), triple negative patients had a worse outcome than ER/Her2 expressing patients (198 c.f. 278 days (p = 0.02)). Less heavily pre-treated patients (≤2 prior treatments) had significantly better survival (328 c.f. 264 days). Patients aged over 65 had better survival 325 c.f. 285 days. 11% experienced grade 3-4 neuropathy, 14% experienced nausea, 19% experienced G3-4 neutropenia, there were no treatment related deaths.

Conclusions

This real world data demonstrates that even in a heavily pretreated population eribulin was associated an OS approaching a year. Eribulin was well tolerated even in patients over 65 and is associated with better survival if used earlier in metastatic patients.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Eisai.

Editorial Acknowledgement

Disclosure

M. Jafri: Advisory board: PharmaMar; Speaker fees: Roche, Pfizer, PharmaMar. H. Kristeleit: Advisory board: Amgen and Roche; Speaker fees: Eisai and Roche. S. Ahmed: Consultancy: Eisai, Novartis, Roche, Pfizer, MSD, AstraZeneca, Takeda. A. Borley: Consultancy: Eisai, Roche, Pfizer. P. Nightingale: Educational grant: Eisai for statistical support. D. Rea: Roche, Novartis, Diachi Sankyo, AstraZeneca, Eisai. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.